Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-707 Combination Therapy in Advanced NSCLC
NCT06412471Phase 2Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tivunatamig in non-small cell lung cancer (NSCLC) (10 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Objective Response Rate at 12 months and Safety and Tolerability at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
tivunatamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06412471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412471.